Latest Posts
Immune and Coagulation Dysregulation in Long COVID
Long COVID, characterized by persistent symptoms following a SARS-CoV-2 infection, affects approximately 10%-20% of individuals, presenting a significant challenge due to the lack of specific diagnostic and therapeutic tools. A recent study published in Science sheds light on the underlying mechanisms of long COVID, revealing dysregulation in the immune system’s
Beyond Dark Chocolate: Flavanol-Rich Foods May Reduce Risk for Essential Hypertension, Blood Clots
Beyond Dark Chocolate: Flavanol-Rich Foods May Reduce Risk for Essential Hypertension, Blood Clots • Flavanol-rich foods like dark chocolate could lower your risk of essential hypertension and blood clots. • A variety of flavanol-rich foods, including tea, berries, and grapes, offer antioxidant and anti-inflammatory cardiovascular benefits. • New research suggests
In Memoriam: Robert Jennejahn (1951–2023)
It is with a heavy heart that we announce the passing of Robert Jennejahn, a valued contributor to Vein Therapy News. His association with our book spanned several issues, during which he made significant contributions. On the 7th of October this year, Robert passed on at the age of 71.
Has your practice seen an increase in blood clots since the COVID vaccines became available?
We would like to hear from you! Please call Gary Pittman Jr at 512-637-0373 or email garypjr@pcinews.com.
Janssen’s Xarelto studied for secondary prevention of VTE in cancer patients
The Janssen Pharmaceutical Companies of Johnson & Johnson recently announced observational data from 8 years of clinical practice showing that the company’s oral Factor Xa inhibitor Xarelto (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a
